AGN,US STOCKS-Wall St sinks as tumbling China equities stoke growth worryUS STOCKS-Wall St sinks as tumbling China stocks stoke growth fearsDeals of the day- Mergers and acquisitionsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video        US STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       July 27 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:US STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video         Deals of the day- Mergers and acquisitionsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video        US STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       July 27 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:US STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video        * Oil prices, commodities lower following China equity selloffDeals of the day- Mergers and acquisitionsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video        US STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       July 27 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:US STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video          US STOCKS-Wall St sinks as tumbling China stocks stoke growth fearsDeals of the day- Mergers and acquisitionsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video        US STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       July 27 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:US STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video         Deals of the day- Mergers and acquisitionsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video        US STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       July 27 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:US STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video        * Oil prices, commodities lower following China equity selloffDeals of the day- Mergers and acquisitionsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video        US STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       July 27 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:US STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video         * Indexes down: Dow 0.73 pct, S&P; 0.5 pct, Nasdaq 0.89 pct   (Updates to afternoon trading)US STOCKS-Wall St sinks as tumbling China stocks stoke growth fearsDeals of the day- Mergers and acquisitionsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video        US STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       July 27 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:US STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video         Deals of the day- Mergers and acquisitionsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video        US STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       July 27 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:US STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video        * Oil prices, commodities lower following China equity selloffDeals of the day- Mergers and acquisitionsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video        US STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       July 27 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:US STOCKS-Wall St drops as China stock slump stokes growth fearsUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video       US STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      * Oil prices, commodities lower following China equity selloffUS STOCKS-Wall St drops as China stock slump stokes growth fearsUPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video      UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     * Indexes end down: Dow 0.73 pct, S&P; 0.58 pct, Nasdaq 0.96 pct   (Adds detail on volume, S&P; performance)UPDATE 1-Allergan CEO, fresh off one deal, sets sights on othersUPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video     UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidAllergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video    Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   * Combined entity to have proforma revenue of $26 bln in 2016Allergan CEO, fresh off one deal, sets sights on othersTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  NEW YORK Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video          
AAPL,Apple Watch to be sold at Best Buy stores from AugustApple Watch to be sold at Best Buy stores from August The Apple Watch will be available at stores of Best Buy Co Inc , the largest U.S. consumer electronics chain, starting Aug. 7.  Apple Watch to be sold at Best Buy stores from August The Apple Watch will be available at stores of Best Buy Co Inc , the largest U.S. consumer electronics chain, starting Aug. 7. July 27 The Apple Watch will be available at stores of Best Buy Co Inc, the largest U.S. consumer electronics chain, starting Aug. 7.Apple Watch to be sold at Best Buy stores from August The Apple Watch will be available at stores of Best Buy Co Inc , the largest U.S. consumer electronics chain, starting Aug. 7.  
BBY,Apple Watch to be sold at Best Buy stores from August July 27 The Apple Watch will be available at stores of Best Buy Co Inc, the largest U.S. consumer electronics chain, starting Aug. 7. 
BLK,BlackRock says Italy's regulator dismisses charges over Saipem share sale MILAN, July 27 Italian market regulator Consob has dismissed all charges against fund group BlackRock  and one of its managers over the alleged use of insider information to sell shares in Saipem in 2013, BlackRock said on Monday. 
CI,UPDATE 1-Allergan CEO, fresh off one deal, sets sights on others NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger. 
DAL,BRIEF-Delta Air agrees to acquire China Eastern's new H-sharesDelta to buy 3.55 pct stake of China Eastern for $450 mlnRPT-Delta to buy 3.55 pct stake of China Eastern for $450 mlnUPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline.  UPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline. BEIJING, July 27 Delta Air Lines has agreed to buy an estimated 3.55-percent stake in China Eastern Airlines  for $450 million, the Chinese operator said in stock filing on Monday.UPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline.   RPT-Delta to buy 3.55 pct stake of China Eastern for $450 mlnUPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline.  UPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline. BEIJING, July 27 Delta Air Lines has agreed to buy an estimated 3.55-percent stake in China Eastern Airlines  for $450 million, the Chinese operator said in stock filing on Monday.UPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline.  BEIJING, July 27 Delta Air Lines has agreed to buy an estimated 3.55-percent stake in China Eastern Airlines  for $450 million, the Chinese operator said in stock filing on Monday.RPT-Delta to buy 3.55 pct stake of China Eastern for $450 mlnUPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline.  UPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline. BEIJING, July 27 Delta Air Lines has agreed to buy an estimated 3.55-percent stake in China Eastern Airlines  for $450 million, the Chinese operator said in stock filing on Monday.UPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline.    Delta to buy 3.55 pct stake of China Eastern for $450 mlnRPT-Delta to buy 3.55 pct stake of China Eastern for $450 mlnUPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline.  UPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline. BEIJING, July 27 Delta Air Lines has agreed to buy an estimated 3.55-percent stake in China Eastern Airlines  for $450 million, the Chinese operator said in stock filing on Monday.UPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline.   RPT-Delta to buy 3.55 pct stake of China Eastern for $450 mlnUPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline.  UPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline. BEIJING, July 27 Delta Air Lines has agreed to buy an estimated 3.55-percent stake in China Eastern Airlines  for $450 million, the Chinese operator said in stock filing on Monday.UPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline.  BEIJING, July 27 Delta Air Lines has agreed to buy an estimated 3.55-percent stake in China Eastern Airlines  for $450 million, the Chinese operator said in stock filing on Monday.RPT-Delta to buy 3.55 pct stake of China Eastern for $450 mlnUPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline.  UPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline. BEIJING, July 27 Delta Air Lines has agreed to buy an estimated 3.55-percent stake in China Eastern Airlines  for $450 million, the Chinese operator said in stock filing on Monday.UPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline.   * Says Delta Air Lines agrees to acquire 465.91 million new H-shares for HK$3.49 billion ($450.30 million)Delta to buy 3.55 pct stake of China Eastern for $450 mlnRPT-Delta to buy 3.55 pct stake of China Eastern for $450 mlnUPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline.  UPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline. BEIJING, July 27 Delta Air Lines has agreed to buy an estimated 3.55-percent stake in China Eastern Airlines  for $450 million, the Chinese operator said in stock filing on Monday.UPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline.   RPT-Delta to buy 3.55 pct stake of China Eastern for $450 mlnUPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline.  UPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline. BEIJING, July 27 Delta Air Lines has agreed to buy an estimated 3.55-percent stake in China Eastern Airlines  for $450 million, the Chinese operator said in stock filing on Monday.UPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline.  BEIJING, July 27 Delta Air Lines has agreed to buy an estimated 3.55-percent stake in China Eastern Airlines  for $450 million, the Chinese operator said in stock filing on Monday.RPT-Delta to buy 3.55 pct stake of China Eastern for $450 mlnUPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline.  UPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline. BEIJING, July 27 Delta Air Lines has agreed to buy an estimated 3.55-percent stake in China Eastern Airlines  for $450 million, the Chinese operator said in stock filing on Monday.UPDATE 2-Delta to buy 3.55 pct stake of China Eastern for $450 mln BEIJING, July 27 Delta Air Lines Inc has agreed to buy 3.55 percent of China Eastern Airlines Corp Ltd  , a move that would make it the first U.S. carrier to own part of a Chinese airline.    
XOM,Australia's LNG double-edged sword shows commodity challenges: RussellExxon Mobil donates $5 mln to North Dakota housing fund WILLISTON, N.D., July 27 A subsidiary of Exxon Mobil Corp donated $5 million on Monday to a North Dakota government housing fund that subsidizes construction of low-cost apartments for teachers and emergency personnel in the state's oil patch.  Exxon Mobil donates $5 mln to North Dakota housing fund WILLISTON, N.D., July 27 A subsidiary of Exxon Mobil Corp donated $5 million on Monday to a North Dakota government housing fund that subsidizes construction of low-cost apartments for teachers and emergency personnel in the state's oil patch. LAUNCESTON, Australia With commodity prices slumping, the local currency slipping and manufacturing jobs disappearing, Australians are starting to question whether they've backed the wrong economic horse.Exxon Mobil donates $5 mln to North Dakota housing fund WILLISTON, N.D., July 27 A subsidiary of Exxon Mobil Corp donated $5 million on Monday to a North Dakota government housing fund that subsidizes construction of low-cost apartments for teachers and emergency personnel in the state's oil patch.  
F,Ford, IBM defeat appeal over apartheid abuses -U.S. courtUPDATE 1-U.S. court rejects appeal of apartheid lawsuits against Ford, IBMFord, IBM defeat appeal over apartheid abuses: U.S. court Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a federal appeals court ruled on Monday.  Ford, IBM defeat appeal over apartheid abuses: U.S. court Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a federal appeals court ruled on Monday. NEW YORK, July 27 Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co  and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a U.S. appeals court ruled on Monday.Ford, IBM defeat appeal over apartheid abuses: U.S. court Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a federal appeals court ruled on Monday.   UPDATE 1-U.S. court rejects appeal of apartheid lawsuits against Ford, IBMFord, IBM defeat appeal over apartheid abuses: U.S. court Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a federal appeals court ruled on Monday.  Ford, IBM defeat appeal over apartheid abuses: U.S. court Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a federal appeals court ruled on Monday. NEW YORK, July 27 Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co  and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a U.S. appeals court ruled on Monday.Ford, IBM defeat appeal over apartheid abuses: U.S. court Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a federal appeals court ruled on Monday.  NEW YORK, July 27 Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co  and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a federal appeals court ruled on Monday.UPDATE 1-U.S. court rejects appeal of apartheid lawsuits against Ford, IBMFord, IBM defeat appeal over apartheid abuses: U.S. court Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a federal appeals court ruled on Monday.  Ford, IBM defeat appeal over apartheid abuses: U.S. court Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a federal appeals court ruled on Monday. NEW YORK, July 27 Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co  and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a U.S. appeals court ruled on Monday.Ford, IBM defeat appeal over apartheid abuses: U.S. court Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a federal appeals court ruled on Monday.   
FCX,UPDATE 1-Indonesia, Freeport agree 6-month export permit extension JAKARTA, July 27 Indonesia and Freeport-McMoRan  reached a deal on Monday that will allow the U.S. mining giant to export up to 775,000 tonnes of copper over the next six months. 
GE,GE sets Sept 4 deadline for bids on Japan leasing unit -sourcesGE sets September 4 deadline for bids on Japan leasing unitAlstom to take 300 mln eur hit to help GE sale throughUPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe.  UPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe. PARIS, July 27 Alstom is to accept a 300 million euro ($333 million) reduction in the price it will get for selling its power turbines unit to General Electric  as a contribution to the U.S. firm's efforts to get antitrust clearance in Europe.UPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe.   Alstom to take 300 mln eur hit to help GE sale throughUPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe.  UPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe. PARIS, July 27 Alstom is to accept a 300 million euro ($333 million) reduction in the price it will get for selling its power turbines unit to General Electric  as a contribution to the U.S. firm's efforts to get antitrust clearance in Europe.UPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe.  TOKYO General Electric Co  has set a Sept 4 deadline for the first round of bids for its Japanese leasing unit, sources with direct knowledge of the matter said on Monday.Alstom to take 300 mln eur hit to help GE sale throughUPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe.  UPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe. PARIS, July 27 Alstom is to accept a 300 million euro ($333 million) reduction in the price it will get for selling its power turbines unit to General Electric  as a contribution to the U.S. firm's efforts to get antitrust clearance in Europe.UPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe.    GE sets September 4 deadline for bids on Japan leasing unitAlstom to take 300 mln eur hit to help GE sale throughUPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe.  UPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe. PARIS, July 27 Alstom is to accept a 300 million euro ($333 million) reduction in the price it will get for selling its power turbines unit to General Electric  as a contribution to the U.S. firm's efforts to get antitrust clearance in Europe.UPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe.   Alstom to take 300 mln eur hit to help GE sale throughUPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe.  UPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe. PARIS, July 27 Alstom is to accept a 300 million euro ($333 million) reduction in the price it will get for selling its power turbines unit to General Electric  as a contribution to the U.S. firm's efforts to get antitrust clearance in Europe.UPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe.  TOKYO General Electric Co  has set a Sept 4 deadline for the first round of bids for its Japanese leasing unit, sources with direct knowledge of the matter said on Monday.Alstom to take 300 mln eur hit to help GE sale throughUPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe.  UPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe. PARIS, July 27 Alstom is to accept a 300 million euro ($333 million) reduction in the price it will get for selling its power turbines unit to General Electric  as a contribution to the U.S. firm's efforts to get antitrust clearance in Europe.UPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe.   TOKYO, July 27 General Electric Co has set a Sept 4 deadline for the first round of bids for its Japanese leasing unit, sources with direct knowledge of the matter said on Monday.GE sets September 4 deadline for bids on Japan leasing unitAlstom to take 300 mln eur hit to help GE sale throughUPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe.  UPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe. PARIS, July 27 Alstom is to accept a 300 million euro ($333 million) reduction in the price it will get for selling its power turbines unit to General Electric  as a contribution to the U.S. firm's efforts to get antitrust clearance in Europe.UPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe.   Alstom to take 300 mln eur hit to help GE sale throughUPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe.  UPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe. PARIS, July 27 Alstom is to accept a 300 million euro ($333 million) reduction in the price it will get for selling its power turbines unit to General Electric  as a contribution to the U.S. firm's efforts to get antitrust clearance in Europe.UPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe.  TOKYO General Electric Co  has set a Sept 4 deadline for the first round of bids for its Japanese leasing unit, sources with direct knowledge of the matter said on Monday.Alstom to take 300 mln eur hit to help GE sale throughUPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe.  UPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe. PARIS, July 27 Alstom is to accept a 300 million euro ($333 million) reduction in the price it will get for selling its power turbines unit to General Electric  as a contribution to the U.S. firm's efforts to get antitrust clearance in Europe.UPDATE 1-Alstom shells out again to keep GE deal on track PARIS, July 27 Alstom is to accept 300 million euros ($333 million) less than previously agreed for its power turbines unit from General Electric as a contribution to the U.S.-based buyer's efforts to win antitrust clearance in Europe.    
GM,GM Korea, union reach tentative wage dealUPDATE 1-GM Korea, trade union reach tentative wage deal SEOUL, July 27 General Motors' South Korean unit tentatively reached an annual wage deal with its labour union on Monday, averting a major strike at one of its key Asian production bases, a union spokesman told Reuters.  UPDATE 1-GM Korea, trade union reach tentative wage deal SEOUL, July 27 General Motors' South Korean unit tentatively reached an annual wage deal with its labour union on Monday, averting a major strike at one of its key Asian production bases, a union spokesman told Reuters. SEOUL, July 27 General Motors' South Korean unit tentatively reached an annual wage deal with its labour union on Monday, averting a major strike at one of its key Asian production bases, a union spokesman told Reuters.UPDATE 1-GM Korea, trade union reach tentative wage deal SEOUL, July 27 General Motors' South Korean unit tentatively reached an annual wage deal with its labour union on Monday, averting a major strike at one of its key Asian production bases, a union spokesman told Reuters.  
GS,UPDATE 1-Goldman Sachs must pay $1.8 mln for reporting failures-FINRAGoldman Sachs must pay $1.8 mln for reporting failures-FINRA A Goldman Sachs Group Inc unit must pay $1.8 million for not reporting "substantial" details about its alternative trading system orders to a system that tracks that information, and also for other lapses, Wall Street's industry-funded watchdog said.  Goldman Sachs must pay $1.8 mln for reporting failures-FINRA A Goldman Sachs Group Inc unit must pay $1.8 million for not reporting "substantial" details about its alternative trading system orders to a system that tracks that information, and also for other lapses, Wall Street's industry-funded watchdog said. July 27 A Goldman Sachs Group Inc unit must pay $1.8 million for not reporting "substantial" details about its alternative trading system orders to a system that tracks that information, and also for other lapses, Wall Street's industry-funded watchdog said.Goldman Sachs must pay $1.8 mln for reporting failures-FINRA A Goldman Sachs Group Inc unit must pay $1.8 million for not reporting "substantial" details about its alternative trading system orders to a system that tracks that information, and also for other lapses, Wall Street's industry-funded watchdog said.  
HUM,UPDATE 1-Allergan CEO, fresh off one deal, sets sights on others NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger. 
IBM,Ford, IBM defeat appeal over apartheid abuses -U.S. courtUPDATE 1-U.S. court rejects appeal of apartheid lawsuits against Ford, IBMFord, IBM defeat appeal over apartheid abuses: U.S. court Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a federal appeals court ruled on Monday.  Ford, IBM defeat appeal over apartheid abuses: U.S. court Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a federal appeals court ruled on Monday. NEW YORK, July 27 Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co  and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a U.S. appeals court ruled on Monday.Ford, IBM defeat appeal over apartheid abuses: U.S. court Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a federal appeals court ruled on Monday.   UPDATE 1-U.S. court rejects appeal of apartheid lawsuits against Ford, IBMFord, IBM defeat appeal over apartheid abuses: U.S. court Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a federal appeals court ruled on Monday.  Ford, IBM defeat appeal over apartheid abuses: U.S. court Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a federal appeals court ruled on Monday. NEW YORK, July 27 Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co  and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a U.S. appeals court ruled on Monday.Ford, IBM defeat appeal over apartheid abuses: U.S. court Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a federal appeals court ruled on Monday.  NEW YORK, July 27 Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co  and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a federal appeals court ruled on Monday.UPDATE 1-U.S. court rejects appeal of apartheid lawsuits against Ford, IBMFord, IBM defeat appeal over apartheid abuses: U.S. court Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a federal appeals court ruled on Monday.  Ford, IBM defeat appeal over apartheid abuses: U.S. court Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a federal appeals court ruled on Monday. NEW YORK, July 27 Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co  and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a U.S. appeals court ruled on Monday.Ford, IBM defeat appeal over apartheid abuses: U.S. court Victims of apartheid in South Africa cannot pursue lawsuits seeking to hold Ford Motor Co and IBM Corp liable for conducting business that helped perpetuate the practice decades ago, a federal appeals court ruled on Monday.   
MCK,UPDATE 1-Allergan CEO, fresh off one deal, sets sights on others NEW YORK, July 27 Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger. 
MON,Syngenta says Monsanto's $2 bln break-up fee comes with caveat * Syngenta: shareholders exposed to non-horizontal antitrust risk 
MS,Morgan Stanley to sell Australian real estate unit to China's CICMorgan Stanley to sell Australian real estate unit to China's CIC SYDNEY Morgan Stanley  said on Monday it has agreed a deal to sell its Australian real estate unit Investa Property Group to China Investment Corp [CIC.UL], a sovereign wealth fund.  Morgan Stanley to sell Australian real estate unit to China's CIC SYDNEY Morgan Stanley  said on Monday it has agreed a deal to sell its Australian real estate unit Investa Property Group to China Investment Corp [CIC.UL], a sovereign wealth fund. SYDNEY, July 27 Morgan Stanley said on Monday it has agreed a deal to sell its Australian real estate unit Investa Property Group to China Investment Corp, a sovereign wealth fund.Morgan Stanley to sell Australian real estate unit to China's CIC SYDNEY Morgan Stanley  said on Monday it has agreed a deal to sell its Australian real estate unit Investa Property Group to China Investment Corp [CIC.UL], a sovereign wealth fund.  
MYL,UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bidTeva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video  * Combined entity to have proforma revenue of $26 bln in 2016Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid TEL AVIV Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video   
NSC,Norfolk Southern profit falls on lower coal, fuel surchargesUPDATE 2-Norfolk South profit dented by lower coal and fuel surcharges CHICAGO, July 27 U.S. railroad Norfolk Southern Corp on Monday reported a lower quarterly net profit as coal freight shipments and fuel surcharge revenue fell, and said coal would continue to weigh on results this year.  UPDATE 2-Norfolk South profit dented by lower coal and fuel surcharges CHICAGO, July 27 U.S. railroad Norfolk Southern Corp on Monday reported a lower quarterly net profit as coal freight shipments and fuel surcharge revenue fell, and said coal would continue to weigh on results this year. CHICAGO, July 27 U.S. railroad Norfolk Southern Corp on Monday reported a lower quarterly net profit due to falling coal freight shipments and a decline in fuel surcharge revenue.UPDATE 2-Norfolk South profit dented by lower coal and fuel surcharges CHICAGO, July 27 U.S. railroad Norfolk Southern Corp on Monday reported a lower quarterly net profit as coal freight shipments and fuel surcharge revenue fell, and said coal would continue to weigh on results this year.  
PFE,Lilly continues test of HDL cholesterol drug, on panel's advice July 27 Eli Lilly and Co on Monday said it would continue a large study of its high-profile experimental drug to raise "good" HDL cholesterol and lower "bad" LDL cholesterol, acting on the recommendation of a data monitoring committee. 
PG,P&G; to name David Taylor CEO - WSJUPDATE 2-P&G; to name David Taylor CEO -WSJ July 27 Procter & Gamble Co will replace Chief Executive A.G. Lafley with company veteran David Taylor in a widely expected appointment that could be announced as soon as Thursday, the Wall Street journal reported.  UPDATE 2-P&G; to name David Taylor CEO -WSJ July 27 Procter & Gamble Co will replace Chief Executive A.G. Lafley with company veteran David Taylor in a widely expected appointment that could be announced as soon as Thursday, the Wall Street journal reported. July 27 Procter & Gamble Co will name David Taylor as its next chief executive, succeeding A.G. Lafley, the Wall Street journal reported.UPDATE 2-P&G; to name David Taylor CEO -WSJ July 27 Procter & Gamble Co will replace Chief Executive A.G. Lafley with company veteran David Taylor in a widely expected appointment that could be announced as soon as Thursday, the Wall Street journal reported.  
KO,U.S. private sector vows to ante up on climate financeU.S. private sector vows to ante up on climate finance WASHINGTON Some of the biggest U.S. corporate names on Monday offered their support - and billions of dollars in green financing pledges - to buttress the Obama administration's quest for a global agreement on combating climate change.  U.S. private sector vows to ante up on climate finance WASHINGTON Some of the biggest U.S. corporate names on Monday offered their support - and billions of dollars in green financing pledges - to buttress the Obama administration's quest for a global agreement on combating climate change. WASHINGTON, July 27 Some of the biggest U.S. corporate names on Monday offered their support - and billions of dollars in green financing pledges - to buttress the Obama administration's quest for a global agreement on combating climate change.U.S. private sector vows to ante up on climate finance WASHINGTON Some of the biggest U.S. corporate names on Monday offered their support - and billions of dollars in green financing pledges - to buttress the Obama administration's quest for a global agreement on combating climate change.  
WU,Western Union restarts money transfer service in Greece July 27 Western Union Co said on Monday it had restarted its money transfer service in Greece, allowing customers there to receive funds from overseas at some locations. 
